Galderma Acne Ingredient Switch Receives NDAC Review In April
This article was originally published in The Pink Sheet Daily & The Rose Sheet
Executive Summary
FDA schedules an April 15 NDAC to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.